Although the National Growth Fund has officially concluded following its third round of funding, several million euros remain available for promising new initiatives—especially in the field of Health & Care.

Liver toxicity is the number one reason for drugs to be retracted from the market. More reliable methods for predicting drug- induced liver toxicity will not only save drug development costs by detecting liver toxic drugs earlier, but will also spare patients from potential severe side effects due to liver toxicity.

On May 22, our General Director Bernard Mulder had the honor of joining His Majesty King Willem-Alexander of the Kingdom of the Netherlands, Prof. Yoshiki Sawa, Chairman of the Organization for Advanced Healthcare Innovation (Nakanoshima Qross), and H.E. Ms. Reinette Klever, Minister for Foreign Trade and Development Cooperation of the Netherlands.